Ju‐Sheng Lin

3.0k citations
64 papers · 1.6k indexed · 1 hit paper · h-index 16

Ju‐Sheng Lin

62 papers receiving 1.6k citations

Hit Papers

Hepatogastroenterology8352012202620162021250500750

Peers

Ju‐Sheng Lin
Comparison fields: 5 of 106
  • Hepatology 283
  • Cancer Research 255
  • Gastroenterology 89
  • Oncology 361
  • Virology 55
Replace Mee Soo Chang with:
Mee Soo Chang South Korea
Kazuo Hatsuse Japan
Sook Hee Hong South Korea
Linda A. Lee United States
Alfredo Minguela Spain
Xueping Wang China
Dermot Kelleher Ireland
Norihiko Yamamoto Japan
Volker Ellenrieder Germany
Bernd Kronenberger Germany
Ju‐Sheng Lin relative to Mee Soo Chang South Korea Mee Soo Chang's profile →
Citations per field
00.5×5.5×
Mee Soo Chang · 1×
Citations per year

Countries citing papers authored by Ju‐Sheng Lin

Since Specialization
Citations

This map shows the geographic impact of Ju‐Sheng Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ju‐Sheng Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ju‐Sheng Lin more than expected).

Fields of papers citing papers by Ju‐Sheng Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ju‐Sheng Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ju‐Sheng Lin. The network helps show where Ju‐Sheng Lin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ju‐Sheng Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ju‐Sheng Lin Line = papers co-authored together Ju‐Sheng Lin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 201578
2 201460
3 201429
4 201444
5 201311
6 201211
7 20124
8 201119
9 201119
10 20113
11 201028
12 20108
13 20081
14 20087
15 20071
16
[Relationship between death receptor 5 and apoptosis in hepatocellular carcinoma].
20061
17 20062
18
[Correlation between polymorphism of TaqI of ET-1 gene and cirrhotic portal hypertension].
20031
19 20037
20
[Inhibition of the replication of hepatitis B virus in vitro by a novel nucleoside analogue (beta-L-D4A)].
20030

About Ju‐Sheng Lin

Ju‐Sheng Lin is a scholar working on Hepatology, Virology and Epidemiology, having authored 64 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (30 papers), Liver Disease Diagnosis and Treatment (13 papers), Hepatitis C virus research (11 papers), RNA modifications and cancer (9 papers), MicroRNA in disease regulation (7 papers), RNA Interference and Gene Delivery (6 papers), HIV/AIDS drug development and treatment (6 papers) and Liver physiology and pathology (5 papers). The work is most often cited by research in Hepatology (283 citations), Cancer Research (255 citations) and Gastroenterology (89 citations). Ju‐Sheng Lin has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Xingxing He, Ying Chang, Chuanrui Xu, Shuzhen Sun, Dong Xu, Yung‐Chi Cheng, Jiazhi Liao, Chung K. Chu, John C. Drach and Jiří Žemlička.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026